Updated: December 8, 2023
Generic name |
oseltamivir | |
---|---|---|
Strength |
30 mg, 45 mg, 75 mg (capsules) and 6 mg/mL (oral suspension) |
|
Form |
capsules |
Special Authority criteria |
Approval period |
---|---|
For the treatment and prophylaxis of influenza A and B during an outbreak among permanent residents of licensed long-term care facilities (i.e., PharmaCare Plan B facilities) |
A 5-day treatment course or up to a 14-day preventive course during the influenza season |
For the treatment of patients at high risk* of complications from influenza infection who have either:
OR
AND Treatment should be initiated within 48 hours of symptom onset to optimize the benefits of oseltamivir. Notes: *Patients at high risk of complications from influenza are defined as follows:
|
A 5-day treatment course during the influenza season |